WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.
Praveen Tipirneni, M.D., president and CEO of Morphic, will provide an overview of the company, its innovative platform for designing integrin oral inhibitors, and anticipated milestones in 2019.
Morphic is developing highly differentiated molecules for the treatment of autoimmune diseases, fibrotic diseases, and cancer. In 2018, Morphic announced the completion of a $80 million Series B financing and entered into a research and development collaboration with AbbVie designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.
Date: Wednesday, January 9, 2019
Time: 11:00 a.m. PT
Location: Westin St. Francis, Elizabethan D
About Morphic Therapeutic
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on integrin biology breakthroughs from the lab of noted entrepreneur and scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc., that facilitates the rapid and iterative design of clinical candidates. For more information, visit www.morphictx.com.
Robert E. Farrell, Jr., VP Finance and Ops and Treasurer
Jackie Byrne, Ten Bridge Communications